BI 443651

Drug Profile

BI 443651

Latest Information Update: 03 Dec 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 25 Nov 2016 Boehringer Ingelheim plans a phase Ib trial for Chronic obstructive pulmonary disease and Cystic fibrosis in Germany and United Kingdom (Inhalation) (NCT02976519)
  • 01 Jun 2016 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (Inhalation) (NCT02706925)
  • 01 Mar 2016 Phase-I clinical trials in Chronic obstructive pulmonary disease (In volunteers) in Germany (Inhalation) (NCT02706925)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top